Abstract: A compound of the formula 1

Abstract: A retainer for holding a plurality of waterfowl decoys has at least three arms pivotally mounted on a pin so as to be moveable between a first position in which the arms are aligned parallel to each other for storage and a open position in which the arms are angularly oriented with respect to one another. The device includes a locking pin for fitting into a first set of holes in the three arms for locking the arms in the first position and fitting into a second set of holes in the arms for locking the arms in the second position. The device further includes a moveable post at the end of each arm for retaining a waterfowl decoy and a ratchet engagement between the post and the arm to permit manual movement of the post with respect to the arm to its desired orientation to retain the post in the desired orientation after it has been positioned without requiring the tightening or untightening of screws and the like.

Abstract: The invention relates to compounds of formula I 1

Abstract: A skin moisturizing composition comprising water, a skin moisturizer, a water soluble hydroxyalkylcellulose polymer and additives is free of fats and oils. The composition derives substantial water-barrier properties from the water soluble hydroxyalkylcellulose polymer.

Abstract: A retainer for holding a plurality of waterfowl decoys has at least three arms pivotally mounted on a pin so as to be moveable between a first position in which the arms are aligned parallel to each other for storage and a open position in which the arms are angularly oriented with respect to one another. The device includes a locking pin for fitting into a first set of holes in the three arms for locking the arms in the first position and fitting into a second set of holes in the arms for locking the arms in the second position. The device further includes a moveable post at the end of each arm for retaining a waterfowl decoy and a ratchet engagement between the post and the arm to permit manual movement of the post with respect to the arm to its desired orientation to retain the post in the desired orientation after it has been positioned without requiring the tightening or untightening of screws and the like.

Abstract: A conveyor for transporting objects sensitive to electrostatic discharge. In one embodiment, the present invention relates to a roller conveyor with conductive rollers in electrical communication with an electrical ground. The rollers preferably have about 105 ohms resistance from the outer diameter to the inner diameter to ensure that electrostatic charges built up on the conveyed object can flow to ground, yet not flow too quickly. In another embodiment, the roller shafts are supported on highly conductive bushings that provide a path to electrical ground that is preferably less that 104 ohms. In yet another embodiment, the roller shafts are driven by a conductive pulley that minimizes the build-up of electrostatic charge as a result of a triboelectric effect with the drive belt.

Abstract: The present invention relates to novel aminomethylene substituted non-aromatic heterocycles and, specifically, to compounds of formula (Ia) or (Ib) wherein W, R1, R2, R3, A, X′, Y′ and Z′ are as defined in the specification, and to intermediates used in the syntheses of such compounds. The novel compounds of formulae (Ia) and (Ib) are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

Abstract: A compound of the formula wherein X, Y, Z, R2 and R3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated.

Abstract: The present invention relates to compounds of formula I: and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.

Abstract: The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

Abstract: The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4(trifluoromethylphenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT1D rector. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT1D receptor selective antagonist is therapeutically indicated.

Abstract: A method is provided for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, cluster headache, migraine, pain, obsessive-compulsive disorder, panic disorder, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula (I) or the pharmaceutically acceptable salt thereof; wherein X, Y, Z, R2 and R3 are as defined herein.

Abstract: The present invention relates to compounds of formula I, 1

Abstract: A conveyor (20, 120, 220, 320) for transporting objects sensitive to electrostatic discharge. In one embodiment, the present invention relates to a slippable roller conveyor (20, 120, 220, 320) with conductive slippable rollers (30, 30′) in electrical communication with an electrical ground (60). The slippable rollers (30, 30′) preferably have about 105 ohms resistance from the outer surface (40) to the inner diameter (34) to ensure that electrostatic charges built up on the conveyed object can flow to ground, yet not flow too quickly. In another embodiment, the roller shafts (35) are supported on highly conductive bushings that provide a path to electrical ground that is preferably less than 104 ohms. In yet another embodiment, the roller shafts (35) are driven by a conductive pulley (65) that minimizes the build-up of electrostatic charge as a result of a triboelectric effect with the drive belt (70).

Abstract: The present invention relates to lactam derivatives of the formula 1

Abstract: In office equipment such as printers and copiers, a single machine “platform” is available as a number of distinct variants (copier, printer, facsimile, MICR printer). Different variants may require different types of marking material cartridges, or other replaceable units. To prevent the installation of an unsuitable cartridge in a machine, each cartridge defines a distinguishing configuration of convex or concave engagement structures, arranged in a circle, but whereby no more than one-half of the circumference of the circle is taken up by the engagement structures. The engagement structures engage with complementary structures inside a suitable machine, and can assist in driving a rotation of the cartridge within the machine.

Abstract: The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.

Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a GABA-A alpha ⅔ agonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a GABA-A alpha ⅔ agonist, and an SRI antidepressant agent.

Abstract: The present invention relates to a method of treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal by administering to the mammal a neurotransmitter-inducing or precursor agent in combination with an (SRI) antidepressant or an anxiolytic agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a neurotransmitter-inducing or precursor agent, and an SRI antidepressant or anxiolytic agent.

Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.